Director Interview With James Fair
We caught up with Fusion antibodies to learn more about the business and who they are, Fusion offers a complete range of antibody-related services in Discovery, Engineering, and Supply and has guided hundreds of projects through critical preclinical stages.
Fifteen of our client’s projects have advanced to clinical stages, some as far as Phase II.
We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in the early-stage discovery of biologics.
Fusion antibodies said: “We offer this personalised service because we know that investment at the early stages saves not only millions of dollars but also months, even years of time, on projects that go awry at later stages of development.
On the 28th April 2020, the company announced they had issued £3m of equity at 90p per share, funds will be used to expand the existing proof-of-concept work on the Mammalian Antibody Library to include COVID-19, the existing oncology targets and for general working capital purposes
Paul Kerr, CEO of Fusion Antibodies plc commented: “We are delighted to be able to announce this oversubscribed placing which will help us in our critical work. In these currently extremely challenging times, we now have the resources to undertake the additional proof-of-concept work on the Mammalian Antibody Library Discovery Platform in respect of COVID-19, as well as for our existing oncology targets, whilst continuing to support our clients in their vital role. We remain confident that our products and services can help to accelerate finding a solution to this global health crisis.”
We caught up with Fusions CFO James Fair to discuss the latest developments here.
Fusion Antibodies CEO sees ‘enormous value’ in discovery platform as it expands to include COVID-19
The author was not remunerated nor holds shares in the company
